Polymyxin B/Neomycin/Hydrocortisone Oph Susp Rx
Generic Name and Formulations:
Polymyxin B sulfate 10000 Units, neomycin 0.35% (as sulfate), hydrocortisone 1%; per mL; contains thimerosal.
Various generic manufacturers
Indications for Polymyxin B/Neomycin/Hydrocortisone Oph Susp:
Ocular inflammation associated with infection.
1–2 drops or small amount of oint every 3–4 hours (may use susp more often); max 20mL or 8g per therapeutic course.
Ocular fungal, viral or mycobacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor IOP, for secondary infections, and avoid abrupt cessation in prolonged use. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antibiotics + steroid.
Local irritation, sensitization, masks infection, delays healing; in prolonged use: increased IOP, cataracts, corneal perforation, optic nerve damage.
Formerly known under the brand name Cortisporin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma